June 16, 2025 10:09 AM EDT
Deals
China

NextCure inks ADC deal with Shang­hai drug­mak­er

Jaimy Lee

Deputy Editor

NextCure will be pay­ing up to $745 mil­lion for the ex-Greater Chi­na rights to an ear­ly-stage an­ti­body-drug con­ju­gate de­vel­oped by a Shang­hai-based drug de­vel­op­er. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

Roche moves ahead with Phase 3 Parkin­son’s study de­spite mixed tri­al re­sults

Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times